Taken together, these data suggest that MUC1 mRNA-based vaccination, especially in combination with inhibition of the immune checkpoint CTLA-4, is a promising immunotherapeutic approach for the treatment of triple-negative breast cancer. This evidence concerns the gene MUC1 and triple-negative breast carcinoma.